CYCC icon

Cyclacel Pharmaceuticals

17 hedge funds and large institutions have $1.39M invested in Cyclacel Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
5
Increased
5
Reduced
2
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Vanguard Group
1
Vanguard Group
Pennsylvania
$604K 347,446 +89,026 +34%
VF
2
Virtu Financial
New York
$347K 199,464 +81,820 +70%
Two Sigma Investments
3
Two Sigma Investments
New York
$122K 70,310 +70,310 New
Citadel Advisors
4
Citadel Advisors
Florida
$108K 61,900 +61,900 New
OAM
5
Oxford Asset Management
United Kingdom
$55K 31,827 +31,827 New
RJFSA
6
Raymond James Financial Services Advisors
Florida
$52K 30,125 +10,000 +50%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$37K 21,692
AWS
8
AJ Wealth Strategies
New York
$22K 12,677 +12,677 New
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$21K 12,240 -2,509 -17%
RE
10
RBC Europe
United Kingdom
$9.72K 5,586
Deutsche Bank
11
Deutsche Bank
Germany
$4K 2,803 +2,300 +457%
UBS Group
12
UBS Group
Switzerland
$3K 2,155 -1,200 -36%
CA
13
Calton & Associates
Florida
$3K 2,000 +2,000 New
BlackRock
14
BlackRock
New York
$1K 796
TCM
15
Tang Capital Management
California
-559,900 Closed
TSS
16
Two Sigma Securities
New York
-28,471 Closed
WS
17
Wedbush Securities
California
-27,400 Closed
PAM
18
Panagora Asset Management
Massachusetts
-8,459 Closed
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$0 1
DOA
20
D'Orazio & Associates
Virginia
$0 100
TRCT
21
Tower Research Capital (TRC)
New York
Morgan Stanley
22
Morgan Stanley
New York
$0 260 +31 +14%